Recent Finacing
Recent Raise
Spine BioPharma develops non-surgical, opioid-sparing intradiscal therapies; its lead Remedisc is a 7-amino-acid peptide that downregulates TGFβ1 to treat and slow intervertebral disc degeneration.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at Spine BioPharma.
